ProCE Banner Activity

Advancing Hemophilia Management—Practical Insights for Clinicians

Clinical Thought

The paradigm shift toward personalized treatment strategies in the management of hemophilia necessitates a deep understanding of current and emerging treatment options to improve patient care. In this expert commentary, extended half-life products, non-factor replacement therapies, and gene therapies that could optimize outcomes and significantly improve patient quality of life are reviewed.

Released: March 18, 2025

Expiration: March 17, 2026

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Novo Nordisk and Sanofi.

Novo Nordisk

Sanofi

Disclosure

Primary Author

Mark T Reding, MD

Professor of Medicine
Division of Hematology, Oncology, and Transplantation
Director, Center for Bleeding and Clotting Disorders
University of Minnesota Medical Center
Minneapolis, Minnesota

Mark T. Reding, MD: consultant/advisor/speaker: Bayer, Biomarin, CSL Behring, Genentech, HEMA Biologics, Novo Nordisk, Sanofi, Spark, Takeda; researcher: Bayer, Biomarin.

Guy Young, MD

Director, Hemostasis and Thrombosis Center
Director, Clinical Coagulation Laboratory
Cancer and Blood Disorders Institute
Children's Hospital Los Angeles
Professor of Pediatrics
Division of Hematology/Oncology
Department of Pediatrics
University of Southern California Keck School of Medicine
Los Angeles, California

Guy Young, MD: consultant/advisor/speaker: ASC Biotherapeutics, BioMarin, CSL Behring, Genentech/Roche, Hema Biologics, Novo Nordisk, Octapharma, Pfizer, Sanofi Genzyme, Spark, Takeda.